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ABSTRACT 
The design and synthesis of two Janus-type heterocycles with capacity to simultaneously 
recognize guanine and uracyl in G-U mismatched pairs through complementary hydrogen 
bond pairing is described. Both compounds were conveniently functionalized with a 
carboxylic function and efficiently attached to a tripeptide sequence by using solid-phase 
methodologies. Ligands based on the derivatization of such Janus compounds with a small 
aminoglycoside, neamine, and its guanidinylated analogue have been synthesized, and their 
interaction with Tau RNA has been investigated by using several biophysical techniques, 
including UV-monitored melting curves, fluorescence titration experiments and 1H NMR. 
The overall results indicated that Janus-neamine/guanidinoneamine showed some 
preference for the +3 mutated RNA sequence associated with the development of some 
tauopathies, although preliminary NMR studies have not confirmed binding to G-U pairs. 
Moreover, a good correlation has been found between the RNA binding affinity of such 
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Janus-containing ligands and their ability to stabilize this secondary structure upon 
complexation.  
 
INTRODUCTION 
Targeting RNA with small molecules, particularly human disease-causing RNAs, has 
enormous potential in medicinal chemistry.1 In addition to the notable case of compounds 
targeting bacterial ribosomal RNA,1 recent examples have demonstrated that the function of 
other RNA sequences can be modulated with synthetic small molecules.2 Similarly to 
proteins, RNA is able to fold local structural motifs such as stem-loops, bulges or internal 
loops into complex three-dimensional architectures, thus generating targetable binding sites 
where ligands can be accommodated. The simultaneous recognition of such targetable 
motifs by compounds based on the combination of fragments is an attractive approach to 
develop ligands with increased RNA affinity and specificity.1,3 Moreover, this fragment-
based approach might also be used to confer them with desirable drug-like properties such 
as cellular permeability.4 
Among the large variety of RNA structural motifs, the G-U wobble base-pair5 plays an 
essential role in many biological processes since it is recognized by proteins and other 
RNAs.6 Despite its comparable thermodynamic stability to Watson-Crick base pairs, 
several studies have revealed that G-U wobble pairs are more prone to base-opening than 
canonical pairs,7 which would facilitate their recognition through complementary hydrogen 
bond pairing by using nicknamed Janus-type molecules. As the two-faced Roman god, 
Janus-type heterocycles have two hydrogen bonding arrays complementary to the faces of a 
given pair of nucleobases.8 Insertion of such compounds between the two nucleobases is 
expected to provide higher affinity and specificity since the number of hydrogen bonds will 
be increased. Most of Janus molecules reported have been incorporated into DNA, PNA 
analogues or peptides with negatively-charged backbone with the aim of forming triplex or 
duplex structures upon bifacial recognition of target nucleobases.9 Diaminotriazine 
conjugation to an acridine derivative has also been explored for targeting U-U mismatch 
sites in CUG repeats in RNA associated with the development of myotonic dystrophy type 
1 disease.10  
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Figure 1. A) Sequences and secondary structure of wild-type (wt) and +3, +13, +14 and +16 
mutated Tau stem-loop RNAs. Exonic sequences are shown in capital letters and intronic sequences 
in lower case. Nucleotides involved in base pairs identified previously by NMR are connected by a 
dash.12a,13c B) Schematic representation of Janus A and Janus B heterocycles binding to G-U 
mismatched pairs. 
 
Of current interest to our laboratory11 is the development of ligands for the RNA secondary 
structure located at the exon 10-5’ intron junction of Tau pre-mRNA since it has been 
proposed as a therapeutic target for the treatment of several tauopathies, including 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).12,13 
Interestingly, wild-type Tau RNA has two G-U pairs (G+5 and G-4), and some of the 
disease-causing mutations (+13, +14 and +16) found in FTDP-17 patients form additional 
G-U pairs (see Figure 1) that diminish the thermodynamic stability of the stem-loop 
structure. This modifies exon 10 alternative splicing and, as a consequence, the correct ratio 
of tau protein isoforms is altered, which leads to dementia.14 Significantly, early NMR 
studies reported by Varani et al.12a suggested that wobble G-U pairs are only formed in the 
case of +13 and +14 mutated sequences, whereas G-1 (+16 mutated sequence) and G+5 and 
G-4 (wt, +3 and +16) are not paired with their faced U’s. On the basis of these precedents, 
we have envisaged that such G-U pairs might be used to selectively target Tau RNA with 
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Janus-type molecules designed to recognize both mismatched nucleobases (Figure 1). It is 
expected that stabilization of the mutated RNA sequences upon ligand binding might allow 
the physiological balance of tau isoforms to be restored and consequently the tauopathy to 
be treated.11-14 We report herein the design and synthesis, and, to the best of our knowledge, 
the first Janus-type molecules (denoted in this work as Janus A and Janus B) capable of 
hydrogen bond to G’s and U’s in G-U mismatched pairs. Ligands based on the 
derivatization of such Janus compounds with a small aminoglycoside, neamine, and its 
guanidinylated analogue have been synthesized, and their interaction with Tau RNA has 
been investigated by using several biophysical techniques. 
 
RESULTS AND DISCUSSION 
Synthesis and characterizacion of Janus building blocks 1 and 2. 
As shown in Figure 1, the heteroaromatic bicyclic Janus A molecule contains donor-
acceptor-acceptor and acceptor-donor H-bond arrays. Regarding Janus B molecule we 
chose to incorporate both faces in separate aryl rings linked through a single bond, which 
might confer some degree of rotational flexibility. It should be noted that the formation of 
an intramolecular H-bond between the exocyclic amino function of cytosine and the 
adjacent nitrogen of the diaminotriazine heterocycle might serve to keep it planar and semi-
rigid, which might be important for recognition of G-U mismatched pairs. In this case, 
diaminopurine face (donor-acceptor-donor H-bond array) was chosen to afford three 
Watson-Crick hydrogen bonds upon binding to uracyl, whereas cytosine face (donor-
acceptor-acceptor H-bond array) can form the three typical Watson-Crick hydrogen bonds 
with guanine, as in Janus A. Hence, Janus A and Janus B-containing compounds might 
have the potential to form 5 or 6 hydrogen bonds with G-U mismatched pairs, respectively. 
Since the final aim is to combine such Janus structures with other molecules such as 
peptides or glycosides to generate ligands with increased RNA specificity, we planned the 
synthesis of two Janus monomers (compound 1 for Janus A in Scheme 1 and compound 2 
for Janus B in Scheme 2) with a carboxylic function to allow further derivatization in 
solution or in a solid-phase through the formation of an amide bond.  
Compound 1 was prepared in 11 steps and 68% average stepwise yield (Scheme 1). First, 
barbituric acid was converted into 2,4,6-trichloropyrimidine-5-carbaldehyde (3) by 
Vilsmeier reaction with phosphorus oxychloride and DMF.15 Nucleophilic aromatic 
substitution with ethyl aminobutyrate (1 mol equiv.) at 0ºC in the presence of triethylamine 
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afforded simultaneous substitution at positions 2 and 4 in the pyrimidine ring. Although 
monosubstitution at position 4 was favoured at low temperature (-78ºC), MS analysis 
showed the formation of several side products because of the nucleophilic attack of 
triethylamine. This side-reaction was minimized by using a sterically-hindered base, N,N-
diisopropylethylamine, which yielded compound 4a in 60% after flash column 
chromatography. This compound differs from its regioisomer 4b (SNAr at position 2) in the 
1H NMR chemical shift of the amino function (δ: 9.36 ppm for 4a and 6.28 ppm for 4b). 
The 1D NOE irradiation of the proton at 9.36 ppm showed a clear NOE enhancement of the 
aldehyde proton whereas that phenomenon did not occur for the proton at 6.28 ppm, which 
allowed the unambiguous distinction of both isomers.  
A second nucleophilic aromatic substitution with aqueous ammonia afforded compound 5 
in quantitative yield. It is interesting to mention that SNAr occurs exclusively at position 2 
when the reaction is carried out at room temperature for 5 h, whereas a large excess of 
ammonia and higher temperature gives substitution at positions 2 and 6. Similar results 
have been reported with other derivatives of 2,6-dichloropyrimidine that contain an amino 
substituent at position 4 and electronwithdrawing groups (aldehyde or ester) at position 5 of 
the ring.15b,c,16,17 
The next step was the reduction of the aryl chloride group by H2 with 10% Pd-C in the 
presence of sodium acetate, which afforded 6 with 56% yield after chromatographic 
purification. Notably, the aldehyde group was not reduced under the conditions used for 
carrying out catalytic hydrogenation. The primary aromatic amino function was bis-Boc 
protected by reaction with tert-butoxycarbonyl anhydride in DMF in the presence of a 
catalytic amount of DMAP. Besides 7 (29% yield after purification), several side products 
were identified, including those derived from monoprotection of both amino functions. 
Then, the aldehyde was transformed in oxime (8) in 88% yield, and dehydration with 
trifluoroacetic anhydride produced the fluorescent nitrile derivative 9 (79%). The critical 
step of the synthesis route involved the transformation of the free secondary amino function 
into an activated urea derivative to allow cyclization in basic media. To our surprise, this 
aromatic amine function was found very unreactive, since no evidence of reaction was 
obtained when using triphosgene, phosgene, trimethylsilyl isocyanate or chlorosulfonyl 
isocyanate. Reaction with N-chlorocarbonyl isocyanate15b at -10ºC in the presence of 
triethylamine afforded in very low yield the N-chlorocarbonylurea derivative. Finally, 
reaction with trichloroacetyl isocyanate at 0ºC in anhydrous DCM under an Ar atmosphere 
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produced compound 10 in nearly quantitative yield after flash column chromatography. 
Cyclization in a concentrated methanolic solution of ammonia afforded the key compound 
(11, 80% yield) that contains both Janus faces. Boc-protection of the free amino group 
followed by basic hydrolysis of the ester yielded the final JanusA monomer 1 as a clear 
yellow solid, which was fully characterized by HR-ESI MS and 1H and 13C NMR. 
 
 
Scheme 1. Synthesis of Janus A monomer (1). 
 
Compound 2 was prepared in 4 steps and 47% average stepwise yield (Scheme 2) from 
malononitrile, urea and triethyl orthoformate. The key step involved the condensation of the 
nitrile group of 5-cyanocytosine18 with dicyandiamide19 in dry ethylene glycol in the 
presence of KOH at 150ºC for 40 h, which afforded 15 as a brown solid in 54% yield. Mild 
condition reactions, such as those reported for the construction of diaminotriazine from 5-
cyanouracyl19c failed in this case and more energetic conditions were required (e.g. 
prolonged heating at 150ºC or assisted by microwave irradiation). The next step involved 
alkylation of N1 of the cytosine ring with ethyl bromobutyrate by using NaH in DMF. 
Hydrolysis of the intermediate with LiOH afforded the expected Janus B monomer (2). 
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According to previous studies on the incorporation of triazine-containing amino acids onto 
peptides by solid-phase methodologies,20 we decided not to protect the amino groups of the 
triazine moiety. Interestingly, 1H NMR spectra of compound 2 suggests the formation of an 
intramolecular hydrogen bond between the exocyclic amino group of cytosine and the N2 
of the triazine ring, which might protect it from acylation during amide bond formation. 
 
 
Scheme 2. Synthesis of Janus B monomer (2). 
 
Synthesis and characterizacion of Janus-containing ligands. 
Targeting G-U mismatched pairs in Tau RNA or in other RNA secondary structures with 
Janus-type molecules requires conferring them with capacity to selectively recognize RNA 
from DNA. Aminoglycosides fulfill this requirement since they are able to discriminate A-
type from B-type duplexes and have relatively high affinity for RNA.21 However, these 
natural antibiotics lack of RNA sequence specificity, so they are considered promiscuous 
compounds. In spite of this drawback, aminoglycosides are privileged building blocks for 
designing new RNA ligands.22 Recently, we have described a series of ligands for Tau 
RNA based on the combination of neamine and its guanidinylated analogue, 
guanidinoneamine, with heteroaromatic compounds such as acridines and an azaquinolone 
derivative with capacity to recognize unpaired adenines.11 Based on these precedents, our 
next objective was the derivatization of Janus A and B heterocycles with these small 
glycosides. It is worth noting that replacement of the amino functions of neamine by 
guanidinium groups is expected to improve uptake by eukaryotic cells, as well as the RNA 
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binding affinity and stabilizing capacity of the ligands.23 The synthesis of the ligands and 
their structures are shown in Scheme 3. Since the distance between both building blocks 
can be a critical parameter in ligands based on the combination of fragments, we used two 
thiol-containing neamine derivatives (Nea and Nea2)11 differing in the length of the spacer 
between the thiol group and the glycoside core. 
First, both Janus heterocycles were derivatized with a cysteine-containing peptide since the 
reactive thiol group was planned to be used for the attachment to the aminoglycoside via 
the formation of a disulfide linkage. Moreover, the guanidinium and carboxamide groups 
provided by arginine and asparagine, respectively, could generate additional interactions 
with RNA (e.g. hydrogen bonding and/or electrostatic). The tripeptide was assembled on a 
Rink amide p-MBHA resin using standard Fmoc/tBu chemistry. Janus monomers 1 and 2 
were efficiently attached into the N-terminus of the peptide by using HATU as a coupling 
reagent. Cleavage and deprotection with TFA/TIS/H2O 95:2.5:2.5 for 1 h at rt, afforded the 
target compounds (18 and 19, Scheme 3) with high purity according to HPLC analysis. 
This confirms that it is not necessary to protect the exocyclic amino function of cytosine in 
monomer 2. 
Janus-Neamine ligands (20-23) were easily synthesized in a two-step process which 
implicates two consecutive thiol-disulfide exchange reactions. First, thiol-derivatized 
neamine monomers (Nea or Nea2)11 were activated with 2,2’-dithiobis(5-nitropyridine) 
(DTNP)24 under acidic conditions for 15 h under Ar atmosphere. Then, the disulfide 
intermediates were reacted with the thiol-containing Janus-peptide monomers (18 or 19), 
which afforded the desired ligands (20-23) after purification by reversed-phase HPLC 
(yields 21-53%). All the compounds were fully characterized by NMR (1D 1H, COSY, 
TOCSY) and high-resolution ESI mass spectrometry. 
As shown in Scheme 3, the guanidinylated ligands (24-27) were prepared by direct 
guanidinylation of their precursors (20-23) following previously reported procedures.11b,25 
A 40-fold mol equiv. excess of N,N’-di-Boc-N’’-triflylguanidine in the presence of 
triethylamine (240 mol eq.) was used in all cases. After acidic deprotection and purification 
by HPLC, Janus-Guanidinoneamine ligands were obtained (yields: 23-25%) and 
characterized by NMR and HRMS. A significant amount of the triguanidinylated ligand 
was also isolated, which indicates that the guanidinylation reaction did not reach 
completion after 4 days. 
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Scheme 3. Synthesis of Janus-Neamine/Guanidinoneamine ligands. A) Solid-phase synthesis of 
thiol-containing Janus-peptide derivatives; B) synthesis, and C) structure of Janus-containing 
ligands. 
 
Studies on the interaction of Janus-containing ligands with Tau RNA. 
Our next objective was to study the interaction of Janus-Neamine ligands (20-23) and their 
guanidinylated derivatives, Janus-Guanidinoneamine (24-27), with Tau RNA, and in 
particular to evaluate their ability to stabilize Tau RNA. Besides wt we choose two of the 
mutated sequences associated with the development of tauopathies, +3 and +16. As 
previously mentioned, all of them contain two G-U mismatched pairs and +16 mutation 
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generates an additional G-U mismatched pair adjacent to the bulged adenine. UV melting 
experiments were carried out by monitoring the absorbance at 260 nm as a function of 
temperature, which allowed to determine the melting temperature (Tm) as indicative of the 
thermal stability of the RNA secondary structure (Figure 2). ∆Tm values in Table 1 show 
the effect of the ligands on the Tm of RNA upon complexation.  
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Figure 2. A) UV melting profiles for the +3 mutated RNA sequence and its ligand complexes with 
Janus-Neamine and B) Janus-Guanidinoneamine ligands at a [ligand]/RNA ratio of 1.0. C) 
Fluorescence quenching of +3 RNA labelled with 2-aminopurine-2’-deoxyribonucleotide in the 
loop upon addition of increasing concentrations of JanusB-Nea2. Measurements were performed 
with an RNA concentration of 83 nM and ligand concentrations ranging from 0 to 5.43 µM in 10 
mM sodium phosphate buffer pH 6.8, 50 mM NaCl and 0.1 mM Na2EDTA. 
 
Table 1. Melting temperatures (Tm) for the complexation of the ligands with Tau RNAs (1 
µM both in RNA and in ligands in 10 mM sodium phosphate buffer, pH 6.8, 50 mM NaCl 
and 0.1 mM Na2EDTA).  
 
 
 
 
 
 
 
[a] ∆Tm= (Tm of the RNA in the presence of ligand) – (Tm of RNA alone).  
 
 
 
 Tm wt ∆Tm[a] Tm +3 ∆Tm[a] Tm +16 ∆Tm[a] 
No ligand 63.0 - 44.3 - 56.6  
Neamine 62.8 -0.2 48.1 +3.8 56.8 +0.2 
JanusA-Nea 63.1 +0.1 49.3 +5.0 58.5 +1.9 
JanusA-Nea2 63.6 +0.6 50.4 +6.1 57.6 +1.0 
JanusB-Nea 62.8 -0.2 49.6 +5.3 58.0 +1.4 
JanusB-Nea2 63.4 +0.4 50.4 +6.1 57.6 +1.0 
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As shown in Table 1, the effect of Janus-Neamine ligands on the thermal stability of wt 
RNA was almost negligible, being similar to that obtained with the free aminoglycoside. 
However, this effect was positive in the case of the mutated sequences being particularly 
higher with the +3 mutant. Interestingly, the effect of the length of the spacer linking both 
fragments was different depending on the nature of the RNA sequence: the shorter spacer 
caused a greater increase in the Tm values for +3 RNA (∆Tm = +5.0 ºC for JanusA-Nea vs 
∆Tm = +6.1 ºC for JanusA-Nea2) whereas the opposite tendency was found for +16 RNA 
(∆Tm = +1.9 ºC for JanusA-Nea vs ∆Tm = +1.0 ºC for JanusA-Nea2). This suggests that the 
binding site of these compounds might be different depending on the secondary structure of 
the RNA target. To our surprise, the stabilizing ability of the ligands was independent on 
the nature of the Janus-type heterocycle. However, the fact that the Tm values of Janus-
Neamine ligands were slightly higher than those of neamine alone with +3 and +16 RNAs 
seems to suggest that the Janus-peptide fragment might participate in RNA binding. 
Moreover, the higher stabilization of +3 RNA compared with that of +16 (e.g. JanusA-
Nea2, ∆Tm = +6.1 ºC for +3 vs ∆Tm = +1.0 ºC for + 16) might be a consequence of some 
kind of selectivity for this RNA mutated sequence. 
These results prompted us to evaluate the ability of Janus-Guanidinoneamine ligands (24-
27) to stabilize the +3 mutated sequence. As shown in Table 2, guanidinylation of the 
aminoglycoside moiety in Janus-Neamine ligands had always a positive effect on the 
thermal stability of the RNA upon complexation. This effect was particularly important in 
the two ligands with the shorter spacer independently of the Janus heterocycle (∆TmG = 
+3.8 ºC for JanusA-Nea2G4 and JanusB-Nea2G4). However, the additional stabilization 
provided by the guanidinium groups was lower in the case of the ligand with the longer 
spacer that contains JanusB heterocycle (e.g. ∆TmG = +3.3 ºC for JanusA-NeaG4 vs ∆TmG 
= +1.4 ºC for JanusB-NeaG4). 
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Table 2. Melting temperatures (Tm) for the complexation of ligands with target RNAs (1 
µM both in RNA and in ligands in 10 mM sodium phosphate buffer, pH 6.8, 50 mM NaCl 
and 0.1 mM Na2EDTA).  
 
 
 
 
[a] ∆Tm= (Tm of the RNA in the presence of ligand) – (Tm of RNA alone).  
[b] ∆TmG= (Tm of the RNA in the presence of the guanidinylated ligand) – (Tm of the RNA  in the 
presence of the parent non-guanidinylated ligand). 
 
In order to check if the guanidinylated derivatives have higher binding affinity than their 
parent amino compounds, quantitative binding studies were carried out by fluorescence 
titration experiments with the +3 mutated RNA since, as previously mentioned, Tm values 
suggested some preference for this oligoribonucleotide sequence. Based on previous studies 
with other Tau RNA ligands,11 we decided to label +3 Tau RNA with fluorescein since a 
characteristic dose-dependent saturatable quenching in the fluorescence of the RNA is 
usually observed upon complexation with the ligands.26 This approach allows EC50 values 
(the effective ligand concentration required for 50% RNA response) to be obtained by 
fitting the data to a sigmoidal dose-response curve. To our surprise, upon addition of 
increasing concentrations of Janus-containing ligands, either Janus A or Janus B, the 
fluorescence intensity of the fluorescein-labeled RNA increased (upon excitation at 490 
nm) and the maximum was shifted from the typical 517 nm value to 522-525 nm. This 
behaviour might be attributed to the presence of several binding sites in the RNA structure 
or to the interaction of the ligands with fluorescein.26 As an alternative to fluorescein, we 
choose the fluorescent nucleotide analogue 2-aminopurine-2’-deoxyribonucleotide (2-AP), 
which has also been widely used to determine binding affinities for RNA.27 In order to 
minimize alterations in the structure and stability of +3 Tau RNA, we decided to replace the 
adenine base of the loop with 2-AP. Again, changes in 2-AP fluorescence intensity upon 
excitation at 290 nm were measured as a function of the concentration of the ligands. 
 Tm +3 ∆Tm[a] ∆TmG[b] 
No ligand 44.3 - - 
Guanidinoneamine 50.1 +5.8 +2.0 
JanusA-NeaG4 52.6 +8.3 +3.3 
JanusA-Nea2G4 54.2 +9.9 +3.8 
JanusB-NeaG4 51.0 +6.7 +1.4 
JanusB-Nea2G4 54.2 +9.9 +3.8 
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Unfortunately, the inherent fluorescence of JanusA heterocycle hampered the accurate 
determination of EC50 values for JanusA-containing ligands. However, the binding 
affinities of the four JanusB-containing ligands (Table 3) could be determined with 2-AP-
labelled +3 RNA. As shown in Figure 2, the fluorescence of 2-AP decreased upon addition 
of increasing concentrations of the ligands, while the wavelength of the fluorescence 
maximum stayed constant. In this case, the inherent fluorescence of the ligand could be 
efficiently substracted from that of the labelled RNA by repeating the full titration in the 
absence of RNA. Two main conclusions can be drawn from EC50 values reported in Table 
3. First, binding affinities of the ligands are relatively high (120-300 nM) and the length of 
the spacer seems to be a critical parameter since the binding was observed to be stronger for 
the ligands containing the shorter spacer linking both fragments, independently of the 
glycoside moiety (EC50 = 296 nM for JanusB-Nea vs EC50 = 213 nM for JanusB-Nea2). 
Second, guanidinylation of the aminoglycoside had a positive influence on binding affinity, 
which was slightly higher in the case of the ligand with the shorter spacer (EC50 = 213 nM 
for JanusB-Nea2 vs EC50 = 122 nM for JanusB-Nea2G4).  
Table 3. Binding of the ligands to +3 RNA. 
 
 
 
 
[a] All fluorescence measurements were performed in 10 mM sodium phosphate buffer 
pH 6.8, 50 mM NaCl and 0.1 mM Na2EDTA. 
All together, these results show a good correlation between binding affinities of JanusB-
containing ligands and their ability to stabilize Tau RNA. Indeed, the Tm values of +3 RNA 
were increased in the presence of the ligands that had shown higher binding affinities. 
Although binding affinities could not be determined for JanusA-containing ligands, 
according to Tm values reported in Tables 1 and 2, it is expected for these compounds to 
have similar EC50 values than JanusB-containing ligands. 
 
Finally, preliminary NMR studies were carried out to check if Janus-containing ligands can 
recognize G-U mismatched pairs through the formation of complementary hydrogen bonds. 
Ligand EC50 (nM)
[a] 
JanusB-Nea 296.7 + 63 
JanusB-NeaG4 216.2 + 20 
JanusB-Nea2 213.4 + 45 
JanusB-Nea2G4 122.8 + 19 
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On the lack of a well-defined structure for the +3 mutated sequence, we choose wt RNA as 
a model for studying the effect of ligand addition on its 1D 1H NMR spectra, particularly 
on the imino and aromatic region. The structure of this oligoribonucleotide and its 
complexes with neomycin and mitoxantrone have been studied by Varani et al.,12a,13c and 
they can be used as a reference for interpreting changes on the NMR spectra of Tau RNA in 
the presence Janus-containing ligands. As shown in Figure 3, the addition of JanusA-Nea2 
or JanusB-Nea2 caused a general line broadening of all signals but no significant changes 
in the chemical shifts of the imino protons. For example, the imino resonance of G+1 (δ: 
12.65 ppm) and G-1 (δ: 12.84 ppm) were slightly shifted in both RNA-ligand complexes (δ: 
12.55 and 12.78 ppm, respectively), whereas U0 and U+2 imino resonances collapsed into 
a single broad signal. Additionally, changes of the chemical shifts at higher fields than the 
imino resonances, particularly in the region between 5.5 and 8.5 ppm, might be attributed to 
non-exchangeable groups of the neamine moiety. Interestingly, a new signal around δ: 9.55 
ppm (relative integration 1) appeared in the case of JanusB-Nea2 ligand. Taken together, 
these effects on the NMR spectra suggest that Janus-type heterocycles, either JanusA or 
JanusB, do not seem to bind any of the two G-U mismatched pairs in wt RNA since no new 
imino signals are formed in the region between 10 and 14 ppm. However, small changes in 
the chemical shifts of the imino resonances in the upper helical region (e.g., G-1, U0, G+1 
and U + 2) might be related with electrostatic and/or hydrogen bond interactions with RNA 
through the major groove, in a similar way than neomycin does.13a However, we can not 
rule out the formation of selective hydrogen bonds between Janus-type heterocycles and 
other RNA nucleobases.  
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Figure 3. Region of the NMR spectra of wt RNA alone and in the presence of 3 mol equiv. 
of JanusA-Nea2 (A) or JanusB-Nea2 (B) ligands. Imino proton signals are labelled 
according to the numbering scheme shown in Figure 1. Assignments were taken from 
Varani et al.12a,13c The RNA concentration was 40 µM in a 10 mM sodium phosphate 
buffer, pH 6.8, in a 90%/10% H2O/D2O mixture (T = 5ºC). 
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CONCLUSION 
In summary, two Janus-type heterocycles with capacity to recognize guanine and uracyl in 
G-U mismatched pairs through complementary hydrogen bond pairing have been 
described. The key step in the synthesis of Janus A monomer (11 steps, 68% average 
stepwise yield) involved the use of trichloroacetyl isocyanate, that allowed cyclization of 
the intermediate to generate both fused faces. In the case of Janus B monomer (4 steps, 
47% average stepwise yield), condensation of 5-cyanocytosine and dicyandiamine under 
energetic conditions was necessary to generate the diaminotriazine ring. Both compounds 
were conveniently derivatized with a cysteine-containing tripeptide by using solid-phase 
methodologies. Thiol-disulfide exchange reactions on a solution phase were used for the 
assembly of Janus-Neamine ligands differing in the length of the spacer linking the Janus 
moiety and the aminoglycoside. Their guanidinylated derivatives, Janus-Guanidinoneamine 
ligands, were also prepared directly by guanidinylation of their amino parent compounds. 
All Janus-containing ligands were able to stabilize two mutated sequences associated with 
the development of FTDP-17, particularly the +3. Moreover, ligands containing JanusB 
fragment bind with high affinity (EC50 = 120-300 nM) this RNA sequence, showing a good 
correlation between binding affinity ant their stabilizing properties. Although no evidence 
of the formation of hydrogen bonds between the Janus heterocycles and wt RNA can be 
deduced from 1D 1H NMR titration experiments, changes in some chemical shifts confirm 
binding to this target. Efforts are underway to study by NMR spectroscopy the structure of 
the +3 mutated RNA sequence and their complexes with Janus-containing ligands to 
determine if the higher stabilizing ability of these compounds with respect this RNA target 
is related with the recognition of G-U mismatched pairs by Janus heterocycles. 
Furthermore, these Janus-type building blocks might be used in the future to develop 
specific ligands for targeting G-U pairs in other human disease-causing RNAs. 
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EXPERIMENTAL SECTION 
Unless otherwise stated, common chemicals and solvents (HPLC grade or reagent grade 
quality) were purchased from commercial sources and used without further purification. 
Aluminium plates coated with a 0.2 mm thick layer of silica gel 60 F254 were used for thin-
layer chromatography analyses (TLC), whereas flash column chromatography purification 
was carried out using silica gel 60 (230-400 mesh). Reversed-phase high-performance 
liquid chromatography (HPLC) analyses of the compounds were carried out on a Jupiter 
Proteo C18 column (250x4.6 mm, 90 Å 4 µm, flow rate: 1 mL/min) using linear gradients of 
0.045% TFA in H2O (solvent A) and 0.036% TFA in ACN (solvent B). Semipreparative 
purification was carried out in a Jupiter Proteo column (250x10 mm, 10 µm, flow rate: 3 
mL/min), using linear gradients of 0.1% TFA in H2O (solvent A) and 0.1% 
TFA in ACN (solvent B). After several runs, pure fractions were combined and lyophilized. 
NMR spectra were recorded at 25ºC on different spectrometers (300, 400, 500 or 600 MHz) 
using deuterated solvents. Tetramethylsilane (TMS) was used as an internal reference (0 
ppm) for 1H spectra recorded in CDCl3 and the residual signal of the solvent (77.16 ppm) 
for 13C spectra. For DMSO-d6, the residual signal of the solvent was used as a reference in 
1H and 13C spectra. Chemical shifts are reported in part per million (ppm) in the δ scale, 
coupling constants in Hz and multiplicity as follows: s (singlet), d (doublet), t (triplet), q 
(quadruplet), qt (quintuplet), m (multiplet), td (doublet of triplets), br (broad signal). 
Electrospray ionization mass spectra (ESI-MS) were recorded on an instrument equipped 
with single quadrupole detector coupled to an HPLC, and high-resolution (HR) ESI-MS on 
a LC/MS-TOF instrument. 
 
Synthesis of Janus A monomer (1). 
2,4,6-trichloropyrimidine-5-carbaldehyde (3). Barbituric acid (30 g, 0.234 mol) was 
slowly added to a stirred solution of POCl3 (140 mL, 1.51 mol) in DMF (25 mL, 0.234 
mol) at room temperature under Ar, which rapidly acquired a yellow colour. After refluxing 
for 15 h, the mixture was allowed to cool down to room temperature and evaporated in 
vacuo to remove most of POCl3 excess. Then, the residue was carefully poured over 
crushed ice while maintaining vigorous stirring, and the resulting brown precipitate was 
filtered and dried under vacuum. After flash column chromatography (gradient: 0-50% 
AcOEt in hexane), the desired product was obtained as a brown solid (21 g, 42%) and used 
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in the next step without further purification. TLC: Rf (10% AcOEt/Hexane): 0.43; m.p: 
166-169ºC; 1H NMR (400 MHz, CDCl3) δ (ppm): 10.42 (1H, s); 
13C NMR (100 MHz, 
CDCl3) δ (ppm): 184.8, 164.2, 161.8, 123.2. 
Ethyl 4-((2,6-dichloro-5-formylpyrimidin-4-yl)amino)butanoate (4a). To a stirred 
solution of 3 (10 g, 47.3 mmol) in DCM (200 mL), a solution of ethyl 4-aminobutyrate 
hydrochloride (7.92 g, 47.3 mmol) and DIPEA (16.1 mL, 94.6 mmol) in DCM (100 mL) 
was slowly added at -78ºC under Ar atmosphere. The resulting mixture, which immediately 
acquired a yellow colour, was stirred at -78ºC for 6 h. Once at rt, the reaction mixture was 
taken up and washed with water (2 x 50 mL) and brine (50 mL). The resulting organic 
phase was dried over anhydrous MgSO4, filtered and concentrated in vacuo to dryness. 
After flash column chromatography (gradient: 2.5-20% AcOEt in hexane), the desired 
compound (4a) was obtained as a yellow crystalline solid (8.53 g, 60%). In addition, 
regioisomer 4b was also isolated as a minor product. Data for 4a: TLC: Rf (20% 
AcOEt/Hexane): 0.37; m.p: 91-93ºC; 1H NMR (300 MHz, CDCl3) δ (ppm): 10.3 (1H, s), 
9.36 (1H, br s), 4.15 (2H, q, J =7.2 Hz), 3.67 (2H, dt, J = 6.9 Hz), 2.40 (2H, t, J = 7.2 Hz), 
1.99 (2H, qt, J = 7.2 Hz), 1.27 (3H, t, J = 7.2 Hz); 13C NMR (75 MHz, CDCl3) δ (ppm): 
190.7, 172.8, 166.3, 163.0, 162.1, 106.9, 60.9, 40.8, 31.6, 24.5, 14.4; HRMS (ESI, positive 
mode): m/z 306.0410 [M+H]+ (calcd mass for C11H14Cl2N3O3 [M+H]
+: 306.0412). Data for 
4b: TLC: Rf (20% AcOEt/Hexane): 0.24; 
1H NMR (300 MHz, CDCl3) δ (ppm): 10.25 (1H, 
s), 6.27 (1H, br s), 4.15 (2H, q, J = 7.2 Hz), 3.59 (2H, dt, J = 6.9 Hz), 2.41 (2H, t, J = 7.2 
Hz), 1.99 (2H, qt, J = 7.2 Hz), 1.27 (3H, t, J = 7.2 Hz); 13C NMR (75 MHz, CDCl3) δ 
(ppm): 185.0, 173.1, 165.2, 163.9, 160.5, 114.4, 60.9, 41.5, 31.6, 24.4, 14.4; MS (ESI, 
positive mode): m/z 306.3 [M+H]+ (calcd mass for C11H14Cl2N3O3 [M+H]
+: 306.0412). 
Ethyl 4-((2-amino-6-chloro-5-formylpyrimidin-4-yl)amino)butanoate (5). To a stirred 
solution of 4a (8.33 g, 27.3 mmol) in absolute ethanol (250 mL), 55 mL (819 mmol) of a 
3:7 (v/v) mixture of NH4OH 32 % (w/w) and EtOH were added at room temperature. After 
stirring for 5 h at rt, the reaction mixture was evaporated to dryness. The residue was 
dissolved in AcOEt (100 mL) and washed with water (2 x 50 mL) and brine (50 mL). The 
organic phase was taken up, dried over anhydrous MgSO4, filtered and concentrated in 
vacuo to dryness, providing the desired product as a yellow solid (7.84 g, quantitative 
yield), which was used without futher purification in the next step. TLC: Rf (50% 
AcOEt/Hexane): 0.57; 1H NMR (400 MHz, CDCl3) δ ppm: 10.08 (1H, s), 9.27 (1H, br s), 
5.41 (2H, br s), 4.14 (2H, q, J = 7.2 Hz), 3.55 (2H, dt, J = 6.9 Hz), 2.38 (2H, t, J = 7.2 Hz), 
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1.95 (2H, qt, J = 7.2 Hz), 1.26 (3H, t, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ ppm: 
188.9, 173.1, 166.7, 162.9, 162.4, 102.7, 60.7, 39.9, 31.7, 24.7, 14.3; HRMS (ESI, positive 
mode): m/z 287.0911 [M+H]+ (calcd mass for C11H16ClN4O3 [M+H]
+: 287.0911). 
Ethyl 4-((2-amino-5-formylpyrimidin-4-yl)amino)butanoate (6). To a stirred solution of 
5 (7.80 g, 27.21 mmol) and NaOAc (4.35 g, 108.8 mmol) in absolute EtOH (250 mL), 10% 
Pd/C (521 mg, 0.49 mmol) was added under Ar atmosphere. The reaction mixture was 
stirred at rt under atmospheric pressure of H2 for 15 h. On the basis of TLC analysis, 
additional 10% Pd/C (1 mmol) and NaOAc (54.42 mmol) were required for the reaction to 
reach completion within 6 h. The reaction mixture was filtered through Celite (previously 
washed with EtOH), and the product was eluted with EtOH (50 mL) and MeOH (4 x 50 
mL). The combined filtrates were collected together and evaporated in vacuo affording a 
slightly yellow solid. After flash column chromatography (gradient: AcOEt/hexane (1:1)-
100% AcOEt-2% MeOH/AcOEt) the desired compound (6) was obtained as a white solid 
(3.87 g, 56%). TLC: Rf (AcOEt): 0.28; 
1H NMR (400 MHz, CDCl3) δ ppm: 9.50 (1H, s), 
8.63 (1H, br s), 8.15 (1H, s), 4.14 (2H, q, J = 7.2 Hz), 3.54 (2H, dt, J = 6.8 Hz), 2.39 (2H, t, 
J = 7.2 Hz), 1.96 (2H, qt, J = 7.2 Hz), 1.26 (3H, t, J = 7. Hz); 13C NMR (100 MHz, CDCl3) 
δ ppm: 189.2, 173.1, 166.1, 163.8, 161.8, 107.2, 60.6, 39.3, 31.8, 24.8, 14.4; HRMS (ESI, 
positive mode): m/z 253.1298 [M+H]+ (calcd mass for C11H17N4O3 [M+H]
+: 253.1301). 
Ethyl 4-((2-bis(tert-butoxycarbonyl)amino-5-formylpyrimidin-4-yl)amino)butanoate 
(7). Compound 6 (3.87 g, 15.34 mmol) was dissolved in anhydrous DCM (100 mL) under 
Ar. Then, anhydrous triethylamine (10.2 ml, 67.5 mmol), DMAP (187 mg, 1.53 mmol) and 
Boc2O (7.4 g, 33.75 mmol) were added sequentially. After stirring under Ar for 18 h, the 
reaction mixture was evaporated in vacuo. The residue was dissolved in AcOEt (100 mL) 
and washed with 10% citric acid (50 mL), 10% NaHCO3 (125 mL), and brine (50 mL). The 
organic phase was taken up, dried over anhydrous MgSO4, filtered and concentrated in 
vacuo to dryness. After flash column chromatography (gradient: 0-50% AcOEt in hexane), 
the desired compound (7) was obtained as a white solid (4.1 g, 29.3%). TLC: Rf (AcOEt): 
0.84; m.p: 163-173ºC; 1H NMR (400 MHz, CDCl3) δ (ppm): 9.77 (1H, s), 8.65 (1H, br t), 
8.52 (1H, s), 4.14 (2H, d, J = 7.2 Hz), 3.58 (2H, q, J = 6.8 Hz), 2.37 (2H, t, J = 7.2 Hz), 
1.97 (2H, qt, J = 7.2 Hz), 1.53 (18H, s), 1.26 (3H, t, J = 7.2 Hz); 13C NMR (100 MHz, 
CDCl3) δ (ppm): 190.8, 172.9, 165.3, 161.3, 160.3, 150.4, 110.3, 83.9, 60.7, 39.9, 31.7, 
27.9, 24.6, 14.3; HRMS (ESI, positive mode): m/z 453.2352 [M+H]+ (calcd mass for 
C21H33N4O7 [M+H]
+: 453.2349). 
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Ethyl 4-((2-bis(tert-butoxycarbonyl)amino-5-((hydroxyimino)methyl)pyrimidin-4-
yl)amino)butanoate (8). To a solution of compound 7 (4.22 g, 9.33 mmol) in pyridine (100 
mL), hydroxylamine hydrochloride (1.3 g, 18.7 mmol) was added and the mixture was 
stirred under Ar for 6 h. The solvent was evaporated in vacuo and after several co-
evaporations from toluene, the residue was dissolved in AcOEt (100 mL). The organic 
phase was washed with water (50 mL) and brine (50 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to dryness. The desired compound (8) was obtained as a 
yellow solid (3.85 g, 88%) and used in the next step without further purification. TLC: Rf 
(AcOEt): 0.84; IR (KBr): ν = 3337.8, 1798.5, 1729.6, 1616.1, 1587.1 cm-1; 1H NMR (400 
MHz, CDCl3) δ (ppm): 8.13 (1H, s) 8.13 (1H, s), 8.05 (1H, br s), 8.00 (1H, br s), 4.12 (2H, 
q, J = 7.2 Hz), 3.58 (2H, dt, J = 6.8 Hz), 2.37 (2H, t, J = 7.2 Hz), 1.96 (2H, qt, J = 7.2 Hz), 
1.48 (18H, s), 1.24 (3H, t, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) δ (ppm): 173.3, 160.1, 
157.7, 157.2, 150.9, 147.9, 107.2, 83.2, 60.6, 40.1, 31.8, 28.0, 24.8, 14.3; HRMS (ESI, 
positive mode): m/z 468.2454 [M+H]+ (calcd mass for C21H34N5O7 [M+H]
+: 468.2458). 
Ethyl 4-((2-bis(tert-butoxycarbonyl)amino-5-cyanopyrimidin-4-yl)amino)butanoate 
(9). To a solution of compound 8 (3.85 g, 8.24 mmol) in anhydrous THF (100 mL), 
triethylamine (3.7 mL, 24.72 mmol) was added under Ar. Then, the solution was cooled to 
0ºC and trifluoroacetic anhydride (1.7 ml, 12.36 mmol) was added slowly while stirring. 
The mixture was allowed to warm and stirred for 2 h at rt. The mixture was cooled back to 
0ºC, and cold water (2 mL) was added to destroy the excess of TFAA, and the solvent was 
evaporated in vacuo. The residue was dissolved in AcOEt (50 mL), washed with 10% citric 
acid (25 mL), 10% NaHCO3 (25 mL) and brine (25 mL). The organic phase was taken up, 
dried over anhydrous MgSO4, filtered and evaporated in vacuo. The desired compound (9) 
was obtained after flash column chromatography (gradient: 0-25% AcOEt in hexane) as a 
white solid (2.94 g, 79%). TLC: Rf (25% AcOEt in Hexane): 0.44; m.p: 189-193ºC; IR 
(KBr): ν = 3322.8, 2222.7, 1787.9, 1734.5, 1598, 1580.7 cm-1; 1H NMR (400 MHz, CDCl3) 
δ (ppm): 8.42 (1H, s), 6.12 (1H, br t, J = 5.4 Hz), 4.16 (2H, q, J = 7.2 Hz), 3.57 (2H, dt, J = 
6.8 Hz), 2.40 (2H, t, J = 7.2 Hz), 1.97 (2H, qt, J = 7.2 Hz), 1.51 (18H, s), 1.27 (3H, t, J 
=7.2 Hz); 13C NMR (100 MHz, CDCl3) δ ppm: 173.4, 162.4, 161.2, 159.6, 150.3, 114.9, 
88.6, 84.1, 61.0, 41.0, 31.8, 29.9, 24.2, 14.4; HRMS (positive mode): m/z 450.2352 [M+H]+ 
(calcd mass for  C21H32N5O6 [M+H]
+: 450.2353). 
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Ethyl 4-(1-(2-bis(tert-butoxycarbonyl)amino-5-cyanopyrimidin-4-yl)-3-(2,2,2-
trichloroacetyl)ureido)butanoate (10). To a solution of compound 9 (1 g, 0.636 mmol) in 
anhydrous DCM (5 mL), a solution of trichloroacetyl isocyanate (0.78 mL, 6.36 mmol) in 
anhydrous DCM (9 mL) was added dropwise at 0ºC over a period of 10 min under Ar 
atmosphere. After stirring for 1 h at 0ºC, the reaction mixture was allowed to warm to rt 
and stirred for an additional 5 h. The reaction mixture was cooled to 0ºC and quenched with 
cold water (25 mL). The organic phase was taken up, washed with water (3 x 15 mL), dried 
over anhydrous MgSO4, filtered and evaporated in vacuo. The desired compound (10) was 
obtained after flash column chromatography (gradient: 0-50% AcOEt in hexane) as a 
yellow solid (1.92 g, quantitative). TLC: Rf (AcOEt): 0.93; m.p: 134-137ºC; 
1H NMR (400 
MHz, CDCl3) δ (ppm): 9.53 (1H, s), 4.32 (2H, J = 6.8 Hz), 4.12 (2H, q, J = 7.2 Hz), 2.41 
(2H, t, J = 7.2 Hz), 2.10 (2H, qt, J = 7.2 Hz), 1.57 (18H, s), 1.24 (3H, t, J = 7.2 Hz); 13C 
NMR (100 MHz, CDCl3) δ (ppm): 174.0, 172.7, 163.9, 160.8, 159.1, 158.2, 149.5, 147.5 
104.6, 92.0, 85.1, 60.8, 42.1, 31.6, 27.9, 22.9, 14.3; HRMS (ESI, positive mode): m/z 
637.1336 [M+H]+ (calcd mass for C24H32Cl3N6O8 [M+H]
+: 637.1342). 
Ethyl 4-(4-amino-7-(bis(tert-butoxycarbonyl)amino)-2-oxopyrimido[4,5-d]pyrimidin-
1(2H)-yl)butanoate (11). Compound 10 (1.42 g, 2.23 mmol) was stirred in 7 N NH3 in 
MeOH (50 mL) under Ar atmosphere at -10ºC (ice-NaCl bath) for 2 h. After evaporation in 
vacuo, the resulting solid was dissolved in DCM (30 mL). The organic phase was washed 
with water (3 x 25 mL), dried over anhydrous MgSO4, filtered and evaporated in vacuo. 
The desired compound (11) was obtained as a yellow solid (878 mg, 80.1%) and used 
without further purification in the next step. TLC: Rf (15% MeOH/AcOEt): 0.68; IR 
(NaCl): ν = 3400, 1738.8, 1652.6, 1635.5, 1602.3, 1558.9, 1540 cm-1; 1H NMR (400 MHz, 
CDCl3) δ (ppm): 9.28 (1H, s), 4.27 (2H, t, J = 7.2 Hz), 4.10 (2H, q, J = 7.2 Hz), 2.38 (2H, t, 
J = 7.6 Hz), 2.05 (2H, qt, J = 7.6 Hz), 1.53 (18H, s), 1.22 (3H, t, J = 7.2 Hz); 13C NMR 
(100 MHz, CDCl3) δ (ppm): 173.0, 161.4, 160.4, 158.7, 156.8, 155.9, 150.2, 101.1, 84.5, 
60.6, 41.4, 31.8, 27.9, 23.3, 14.3; HRMS (ESI, positive mode): m/z 493.2411 [M+H]+ 
(calcd mass for C22H33N6O7 [M+H]
+: 493.2405). 
Ethyl 4-(7-(bis(tert-butoxycarbonyl)amino)-4-((tert-butoxycarbonyl)amino)-2-
oxopyrimido[4,5-d]pyrimidin-1(2H)-yl)butanoate (12). To a solution of compound 11 
(878 mg, 2.23 mmol) in anhydrous DCM (30 mL), anhydrous triethylamine (1.62 mL, 
13.38 mmol), DMAP (218 mg, 2.23 mmol) and Boc2O (1.17 g, 6.69 mmol) were added 
under Ar atmosphere. After stirring for 24 h at rt, the colour changed from yellow to brown. 
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The reaction mixture was taken up and the organic phase was washed with water (2 x 25 
mL) 10% citric acid (25 mL), 10%  NaHCO3 (25 mL) and brine (25 mL), then dried over 
anhydrous MgSO4 and filtered. After removal of the solvent under reduced pressure, 
compound 12 was obtained as a brown solid (1.11 g, 90%), which was used without further 
purification in the next step. TLC: Rf (50% AcOEt/Hexane): 0.78; 
1H NMR (400 MHz, 
CDCl3) δ (ppm): 9.42 (1H, s), 4.24 (2H, t, J = 7.2 Hz), 4.09 (2H, q, J = 7.2 Hz), 2.37 (2H, t, 
J = 7.2 Hz), 2.04 (2H, qt, J = 7.2 Hz), 1.54 (18H, s), 1.50 (9H, s), 1.22 (3H, t, J = 7.2 Hz); 
13C NMR (100 MHz, CDCl3) δ (ppm): 172.6, 161.2, 159.3, 158.0, 157.9, 155.6, 149.9, 
148.2 105.6, 84.9, 84.5, 60.7, 41.5, 31.6, 28.1, 27.9, 23.1, 14.3; HRMS (ESI, positive 
mode): m/z 593.2937 [M+H]+ (calcd mass for C27H41N6O9 [M+H]
+: 593.2930). 
4-(7-(Bis(tert-butoxycarbonyl)amino)-4-((tert-butoxycarbonyl)amino)-2-
oxopyrimido[4,5-d]pyrimidin-1(2H)-yl)butanoic acid (1). To a solution of 12 (550 mg, 
0.325 mmol) in a 3:1 (v/v) mixture of H2O/ACN (30 mL), a solution of LiOH (400 mg, 
3.25 mmol) in water (1 mL) was added. After stirring for 1 h at rt, the reaction mixture was 
concentrated in vacuo to remove ACN. The resulting aqueous phase was acidified with 
10% citric acid to pH 3-4, causing the precipitation of a white solid, which was re-dissolved 
with AcOEt (10 mL). The organic phase was taken up and the aqueous phase was washed 
with AcOEt (2 x 10 mL). The combined organic phases were dried over anhydrous MgSO4, 
filtered and evaporated in vacuo. The desired compound (1) was obtained after flash 
column chromatography (gradient: 50-100% AcOEt in hexane, 100% AcOEt-15% MeOH 
in AcOEt) as a yellow solid (130 mg, 27.3%). TLC: Rf (AcOEt): 0.80; m.p: 190-193ºC; IR 
(KBr): ν = 3362.5, 1764.3, 1751.3, 1728.6, 1661.5, 1602.3 cm-1; 1H NMR (400 MHz, 
CDCl3) δ (ppm): 12.10 (1H, br s), 9.43 (1H, s), 4.28 (2H, t, J = 6.8 Hz), 2.44 (2H, t, J = 7.2 
Hz), 2.07 (2H, qt, J = 7.2 Hz), 1.57 (9H, s), 1.51 (18H, s); 13C NMR (100 MHz, CDCl3 ) δ 
(ppm): 177.4, 162.6, 161.2, 159.3, 158.0, 155.5, 149.9, 148.1, 105.6, 84.6, 82.1, 41.3, 31.1, 
28.1, 27.9, 22.9; HRMS (ESI, positive mode): m/z 565.2618 [M+H]+ (calcd mass for 
C25H37N6O9 [M+H]
+: 565.2617). 
 
Synthesis of Janus B monomer (2). 
5-(4,6-Diamino-1,3,5-triazin-2-yl)cytosine (15). To a suspension of compound 14 (5 g, 
36.8 mmol) in ethylene glycol (100 mL), a solution of KOH (4.1 g, 73.5 mmol) and 
dicyandiamide (6.18 g, 73.5 mmol) in ethylene glycol (100 mL) was added dropwise under 
Ar atmosphere over a period of 10 min. The resulting red-brown solution was refluxed at 
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150ºC for 40 h. After evaporation in vacuo, the resulting brown solid was washed with 
water, diethyl ether and EtOH. Finally, compound 15 was obtained as a brown solid (4.53 
g, 54 %) and used without further purification in the next step. 1H NMR (400 MHz, DMSO) 
δ (ppm): 9.46 (1H, br s), 8.51 (1H, s), 8.01 (1H, br s), 6.81 (5H, br s); 13C NMR (100 MHz, 
DMSO) δ (ppm): 167.9, 165.9, 164.2, 156.0, 148.6, 99.2; HRMS (ESI, positive mode): m/z 
221.0893 [M+H]+ (calcd mass for C7H9N8O [M+H]
+: 221.0899). 
4-(5-(4,6-Diamino-1,3,5-triazin-2-yl)cytosine-1(2H)-yl)butanoic acid (2). To a solution 
of compound 15 (630 mg, 2.86 mmol) in anhydrous DMF, NaH 60% dispersion in mineral 
oil (114.4 mg, 2.86 mmol) was added under Ar atmosphere and the reaction mixture was 
stirred at 50ºC for 2 h. Then, ethyl bromobutyrate (450 µL, 3.15 mmol) was slowly added 
dropwise and the mixture was stirred at rt for 15 h. After evaporation in vacuo, the residue 
was dissolved in 30% MeOH in H2O (200 mL) at 70ºC, and then allowed to warm to rt. 
The precipitate was removed by filtration and identified as the starting compound (15). The 
filtrate was evaporated in vacuo affording a solid that contained ethyl 4-(5-(4,6-diamino-
1,3,5-triazin-2-yl)cytosine-1(2H)-yl)butanoate (16), as the major component (80 %) 
according to HPLC-MS analysis. The crude, which was no further purified due to its poor 
solubility in organic solvents, was dissolved in aqueous 1 M LiOH (100 mL) and the brown 
solution was stirred overnight at rt. Then, 10% HCl was added until pH=2. After 
evaporation in vacuo, purification was accomplished by MPLC eluting with a gradient from 
0 to 100 % of B (A: 0.1 % formic acid in H2O and B: 0.1 % formic acid in H2O/ACN 1:1, 1 
L each solvent). Pure fractions by MS-HPLC (linear gradient from 0 to 100 % B in 18 min; 
A: 0.1 % formic acid in H2O and B: 0.1 % formic acid in ACN; Rt= 7.2 min) were 
combined and lyophilized, providing the desired product (2) as a yellow solid (143 mg, 
20%). Data for 16: MS-HPLC (0 a 100% B in 18 min): Rt = 3.5 min; MS (ESI, positive 
mode): m/z 335.04 [M+H]+ (calcd mass for C13H19N8O3 [M+H]
+: 335.1580). Data for 2: 
HPLC (0 a 50% B in 30 min): tR = 14.6 min; 
1H NMR (500 MHz, DMSO) δ (ppm): 12.21 
(1H, br s), 10.74 (1H, br s), 9.10 (1H, br s), 8.79 (1H, s), 7.06 (4H, br s), 3.91 (2H, t, J = 
7.0 Hz), 2.32 (2H, t, J = 7.0 Hz), 1.88 (2H, t, J = 7.0 Hz); 13C NMR (100 MHz, DMSO) δ 
(ppm): 173.9, 167.7, 166.0, 163.9, 154.4, 149.6, 100.3, 49.0, 30.7, 24.4; HRMS (ESI, 
positive mode): m/z 307.1261 [M+H]+ (calcd mass for C11H15N8O3 [M+H]
+: 307.1267). 
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Solid-phase synthesis of Janus-peptide derivatives (18 and 19). 
Fmoc-Asn(Trt)-Arg(Pbf)-Cys(Trt)-resin (17). The peptide was synthesized on a Rink 
amide p-MBHA resin (f = 0.74 mmol/g, 100-200 mesh) using standard Fmoc/tBu 
chemistry with Fmoc-protected amino acids (4 mol equiv.), DIPC (4 mol equiv.) and HOAt 
(4 mol equiv.) for the coupling (2 h, DMF). The following side-chain protecting groups 
were used: Trt (N-Trityl, asparagine; S-Trityl, cysteine), and Pbf (NG-2,2,4,6,7-
pentamethyldihydrobenzofuran-5- sulfonyl, arginine).  
4-(4,7-Diamino-2-oxopyrimido[4,5-d]pyrimidin-1(2H)-yl)-N-[Asn-Arg-Cys-
NH2]butanamide (18). Peptide-bound resin 17 (60 mg, 0.044 mmol, f ~ 0.74 mmol/g) was 
introduced into a polypropylene syringe fitted with a polyethylene disk, treated with 20% 
piperidine in DMF (2 x 10 min), washed successively (30 s washes) with DMF, DCM and 
MeOH and dried directly on a vacuum filtration system. Janus A monomer 1 (33 mg, 0.059 
mmol) was activated with HATU (20.3 mg, 0.053 mmol) and DIPEA (19 µL, 0.111 mmol) 
in the minimum amount of anhydrous DMF for 2 min, and the resulting yellow solution 
was added to the solid support, which was occasionally stirred with a Teflon rod for 4 h at 
RT. After vacuum filtration and washings (3 x DMF, 3 x DCM and 3 x MeOH), side-chain 
deprotection and cleavage from the resin was performed simultaneously with TFA/TIS/H2O 
95:2.5:2.5 (1 mL) for 1 h at RT. Most of the TFA was removed by bubbling N2 into the 
solution, and the resulting residue was poured onto cold ether to precipitate the target 
compound. Analytical HPLC (linear gradient from 0 to 35 % B in 30 min, A: 0.045 % TFA 
in H2O and B: 0.036 % TFA in ACN), revealed the presence of a mail peak (Rt = 13.1 min, 
73%) which was characterized as the desired compound 18. HRMS (ESI, positive mode): 
m/z 637.2744 [M+H]+ (calcd mass for C23H37N14O6S [M+H]
+: 637.2736). 
4-(5-(4,6-Diamino-1,3,5-triazin-2-yl)cytosin-1(2H)-yl)-N-[Asn-Arg-Cys-
NH2]butanamide (19). Peptide-bound resin 17 (34 mg, 0.025 mmol, f ~ 0.74 mmol/g) was 
introduced into a polypropylene syringe fitted with a polyethylene disk, treated with 20% 
piperidine in DMF (2 x 10 min), washed successively (30 s washes) with DMF, DCM and 
MeOH and dried directly on a vacuum filtration system. Janus B monomer 2 (10 mg, 0.032 
mmol) was activated with HATU (11.5 mg, 0.030 mmol) and DIPEA (11 µL, 0.629 mmol) 
in the minimum amount of anhydrous DMF for 2 min, and the resulting yellow solution 
was added to the solid support, which was occasionally stirred with a Teflon rod for 4 h at 
RT. After vacuum filtration and washings (3 x DMF, 3 x DCM and 3 x MeOH), side-chain 
deprotection and cleavage from the resin was performed with TFA/TIS/H2O 95:2.5:2.5(1 
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mL) for 1 h at RT. Most of the TFA was removed by bubbling N2 into the solution, and the 
resulting residue was poured onto cold ether to precipitate the target compound. Analytical 
HPLC (linear gradient from 0 to 35 % B in 30 min, A: 0.045 % TFA in H2O and B: 0.036 
% TFA in ACN), revealed the presence of a mail peak (Rt = 14.1 min, 54%) which was 
characterized as the desired compound 19. HRMS (ESI, positive mode): m/z 679.2953 
[M+H]+ (calcd mass for C24H39N16O6S [M+H]
+: 679.2954). 
 
Synthesis of Janus-Neamine ligands (20-23). 
General procedure. To a solution of 2,2’-dithiobis(5-nitropyridine) (7.8 mg, 25 µmol) in 
THF (2 mL) was added under argon a solution of the neamine thiol derivative (Nea or 
Nea2, 2 µmol)11 in aqueous 0.1 % TFA (1 mL), and the mixture was stirred at rt. After 15 
h, THF was evaporated in vacuo and the remaining yellow solution was diluted with H2O 
(2 mL). The aqueous phase was washed with AcOEt to remove the excess of 2,2’- 
dithiobis(5-nitropyridine) (typically 5 x 2 mL or until no yellow colour was 
detected in the organic phase), lyophilized and dissolved again in aqueous 0.1 % TFA (1 
mL) under argon. Then, a solution of 18 or 19 (2 µmol) in 0.1 % TFA/H2O (1 mL) was 
added over the activated Janus-containing solution, and the mixture was stirred overnight 
under argon at rt. After purification by semipreparative reversed-phase HPLC (linear 
gradient from 0 to 35 % B in 35 min; A: 0.1 % TFA in H2O and B: 0.036 % TFA in ACN) 
and lyophilization, the TFA salt of the desired product was obtained as a white solid. 
JanusA-Nea (20). Yield: 33 %. 1H NMR (600 MHz, D2O) δ (ppm): 8.82 (1H, HAr, s), 5.45 
(1H, H1’, m), 4.63-4.61 (2H, Hα1, Hα3, m), 4.35 (1H, Hα2, m), 4.17 (2H, -N-CH2-, m), 3.99 
(1H, H5’, m), 3.91 (1H, -O-CH2-, m), 3.76 (1H, -O-CH2-, m), 3.65 (1H, H6, m), 3.49 (2H, 
H4, H5, m), 3.40 (3H, H2’, H3’, H4’, m), 3.19 (5H, H6’, Hδ2, Hβ3’, m), 2.94 (1H, Hβ3, m), 2.83 
(1H, Hβ1, m), 2.78 (1H, Hβ1’, m), 2.67 (2H, -S-CH2-, m), 2.40 (2H, -CH2-CO-, m), 2.16 
(2H, H1, H3, m), 1.99 (2H, -N-CH2-CH2-, m), 1.92 (1H, Hβ2’, m), 1.81 (1H, Hβ2, m), 1.61 
(7H, H2,eq, Hγ2, -O-CH2-CH2-, S-CH2-CH2-, m), 1.33 (5H, H2,ax, -O-CH2-CH2-CH2-CH2-, 
m); HRMS (ESI, positive mode): m/z 1073.5088 [M+H]+ (calcd mass for C41H73N18O12S2 
[M+H]+: 1073.5097); analytical reversed-phase HPLC (0 a 35% B in 35 min): Rt = 17.8 
min. 
JanusA-Nea2 (21). Yield: 21 %. 1H NMR (600 MHz, D2O) δ (ppm): 8.77 (1H, HAr, s), 
5.81 (1H, H1’, d, J = 3.8 Hz), 4.61 (1H, Hα3, m), 4.56 (1H, Hα1, t, J = 7.0 Hz), 4.29 (1H, 
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Hα2, m), 4.18 (1H, -O-CH2-, m), 4.07 (2H, -N-CH2-, m), 3.92 (2H, H5’, -O-CH2-, m), 3.68 
(1H, H6, m), 3.49 (2H, H6’, m), 3.41 (3H, H4, H4’, H3’, m), 3.29 (2H, H2’, H5, m), 3.17 (1H, 
Hβ3’, m), 3.06 (2H, Hδ2, m), 2.91 (3H, -S-CH2-, Hβ3, m), 2.77 (1H, Hβ1, m), 2.67 (1H, Hβ1’, 
m), 2.38 (2H, H1, H3, m), 2.33 (2H, -CH2-CO-, m), 1.91 (2H, -N-CH2-CH2-, m), 1.88 (1H, 
Hβ2, m), 1.73 (2H, Hβ2’, H2,eq, m), 1.55 (3H, Hγ2, H2,ax, m); HRMS (ESI, positive mode): 
m/z 1017.4431 [M+H]+ (calcd mass for C37H65N18O12S2 [M+H]
+: 1017.4471); analytical 
reversed-phase HPLC (0 a 35% B in 30 min): Rt = 13.3 min. 
JanusB-Nea (22). Yield: 21%. 1H NMR (600 MHz, D2O) δ (ppm): 8.72 (1H, HAr, s), 5.67 
(1H, H1’, m), 4.61 (1H, Hα3, m), 4.58 (1H, Hα1, t, J = 6.9 Hz), 4.34 (1H, Hα2 , m), 3.96 (1H, 
-O-CH2-, m), 3.88 (3H, -N-CH2-, H5’, m), 3.75 (1H, -O-CH2-, m), 3.63 (2H, H4’, H6, m), 
3.60 (1H, H3’, m), 3.45 (3H, H2’, H4, H5, m), 3.25 (2H, H6’, m), 3.19 (3H, Hδ2, Hβ3, m), 2.94 
(1H, Hβ3’, m), 2.80 (1H, Hβ1’, m), 2.76 (1H, Hβ1, m), 2.67 (2H, -S-CH2-, m), 2.40 (2H, -
CH2-CO-, t, J=7.4 Hz), 2.27 (2H, H1, H3, m), 2.06 (2H, -N-CH2-CH2-, m), 1.89 (1H, Hβ2’, 
m), 1.80 (1H, Hβ2, m), 1.60 (7H, -S-CH2-CH2-, O-CH2-CH2-, H2,eq, Hγ2, m), 1.32 (5H, H2,ax, 
-O-CH2-CH2-CH2-CH2-, m); HRMS (ESI, positive mode): m/z 1115.5302 [M+H]
+ (calcd 
mass for C42H75N20O12S2 [M+H]
+: 1115.5315); analytical reversed-phase HPLC (0 a 35% 
B in 35 min): Rt = 18.5 min. 
JanusB-Nea2 (23). Yield: 53 %. 1H NMR (600 MHz, D2O) δ (ppm): 8.70 (1H, HAr, s), 
5.70 (1H, H1’, m), 4.66 (1H, Hα3, m), 4.60 (1H, Hα1, t, J = 6.9 Hz), 4.34 (1H, Hα2, m), 4.18 
(1H, -O-CH2-, m), 3.99 (2H, H5’, -O-CH2-, m), 3.94 (2H, -N-CH2-, m), 3.65 (2H, H4, H6, 
m), 3.46 (3H, H5, H3’, H4’, m), 3.25 (4H, H2’, H6’, Hβ3, m), 3.17 (2H, Hδ2, t, J=7.3 Hz), 2.99 
(3H, -S-CH2-, Hβ3’, m), 2.81 (1H, Hβ1’, m), 2.73 (1H, Hβ1, m), 2.41 (2H, -CH2-CO-, t, J=7.2 
Hz), 2.25 (2H, H1, H3, m), 2.07 (2H, -N-CH2-CH2-, m), 1.91 (1H, Hβ2’, m), 1.79 (2H, H2,eq, 
Hβ2, m), 1.60 (3H, H2,ax, Hγ2, m); HRMS (ESI, positive mode): m/z 1059.4675 [M+H]+ 
(calcd mass for C38H67N20O12S2 [M+H]
+: 1059.4689); analytical reversed-phase HPLC (0 a 
35% B in 30 min): Rt = 14.8 min. 
 
Synthesis of Janus-Guanidinoneamine ligands (24-27). 
General procedure. Janus-Neamine ligand (20-23, 300 nmol) and 1,3-di-Boc-2- 
trifluoromethylsulfonyl)guanidine (4.7 mg, 12 µmol) were dissolved in a 5:3 (v/v) mixture 
of MeOH/CHCl3 (0.5 mL) under argon atmosphere. Then, triethylamine (10 µL, 72 µmol) 
was added and the reaction mixture was stirred for 4 days at rt under Ar. After evaporation 
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in vacuo, the crude was diluted with DCM (5 mL) and washed with a 10 % aqueous 
solution of citric acid (3×1 mL) and with brine (3×1 mL). The organic phase was taken up 
and dried over anhydrous MgSO4, filtered and concentrated in vacuo to dryness. The crude 
was dissolved in a 1:1 (v/v) mixture of TFA/DCM (0.5 mL) and TIS (12.5 µL, 61 µmol) 
was added. After stirring at rt for 2 h under Ar, the mixture was diluted with toluene (2 mL) 
and evaporated in vacuo. After several co-evaporations from toluene, the residue was 
dissolved in Milli-Q H2O (5 mL) and lyophilized to provide a white solid. Purification was 
carried out by analytical reversed-phase HPLC (linear gradient from 0 to 25% B in 35 min; 
A: 0.045% TFA in H2O and B: 0.036% TFA in ACN), and the TFA salt of the desired 
product was obtained after lyophilization. 
JanusA-NeaG4 (24). Yield: 24 %. 1H NMR (600 MHz, D2O) δ (ppm): 8.81 (1H, HAr, s), 
5.59 (1H, H1’, d, J = 4.0 Hz), 4.61 (2H, Hα1, Hα3, m), 4.35 (1H, Hα2, m), 4.13 (2H, -N-CH2-
, m), 3.98 (1H, -O-CH2-, m), 3.72-3.45 (10H, -O-CH2-, H2’, H3’, H4’, H5’, H6’, H4, H5, H6, 
m), 3.20 (1H, Hβ3, m), 3.16 (2H, Hδ2, m), 2.92 (1H, Hβ3’, m), 2.81 (1H, Hβ1, m), 2.76 (1H, 
Hβ1’, m), 2.66 (2H, -S-CH2-, m), 2.41 (2H, -CH2-CO-, m), 2.25 (2H, H1, H3, m), 1.98 (2H, -
N-CH2-CH2-, m), 1.90 (1H, Hβ2’, m), 1.81 (1H, Hβ2, m), 1.59 (5H, H2,eq, Hγ2, -S-CH2-CH2-, 
m), 1.50 (2H, -O-CH2-CH2-, m), 1.36-1.23 (5H, H2,ax, -O-CH2-CH2-CH2-CH2-, m); HRMS 
(ESI, positive mode): m/z 621.3023 [M+2H]2+ (calcd mass for C45H82N26O12S2 [M+2H]2+: 
621.3024), m/z 414.5366 [M+3H]3+ (calcd mass for C45H83N26O12S2 [M+3H]3+: 414.5375), 
m/z 311.1542 [M+4H]4+ (calcd mass for C45H84N26O12S2 [M+H]+: 311.1551); analytical 
reversed-phase HPLC (0 a 25% B in 35 min): Rt = 23.4 min. 
JanusA-Nea2G4 (25). Yield: 24 %. 1H NMR (600 MHz, D2O) δ (ppm): 8.81 (1H, HAr, s), 
5.66 (1H, H1’, d, J = 4.0 Hz), 4.65 (1H, Hα3, m), 4.62 (1H, Hα1, t, J = 7.0 Hz), 4.35 (1H, 
Hα2, m), 4.21 (1H, -O-CH2-, m), 4.12 (2H, -N-CH2-, m), 3.81 (1H, -O-CH2-, m), 3.73 (2H, 
H5’, H6, m), 3.63 (1H, H2’, m), 3.56 (4H, H3’, H4’, H4, H5, m), 3.47 (2H, H6’, m), 3.23 (1H, 
Hβ3’, m), 3.14 (2H, Hδ2, m), 2.92 (3H, -S-CH2-, Hβ3, m), 2.81 (1H, Hβ1, m), 2.75 (1H, Hβ1’, 
m), 2.40 (2H, -CH2-CO-, m), 2.23 (2H, H1, H3, m), 1.98 (2H, -N-CH2-CH2-, m), 1.90 (1H, 
Hβ2, m), 1.79 (2H, Hβ2’, H2,eq, m), 1.62 (3H, Hγ2, H2,ax, m); HRMS (ESI, positive mode): 
m/z 593.2696 [M+2H]2+ (calcd mass for C41H74N26O12S2 [M+2H]2+: 593.2711), m/z 
395.8489 [M+3H]3+ (calcd mass for C41H75N26O12S2 [M+3H]3+: 395.8500), m/z 297.1388 
[M+4H]4+ (calcd mass for C41H76N26O12S2 [M+H]+: 297.1394); analytical reversed-phase 
HPLC (0 a 25% B in 35 min): Rt = 17.8 min. 
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JanusB-NeaG4 (26). Yield: 25 %. 1H NMR (600 MHz, D2O) δ (ppm): 8.73 (1H, HAr, s), 
5.59 (1H, H1’, d, J= 4.0 Hz), 4.61 (1H, Hα3, m), 4.58 (1H, Hα1, t, J = 6.9 Hz), 4.34 (1H, Hα2 , 
m), 3.98 (1H, -O-CH2-, m), 3.91 (2H, -N-CH2-, m), 3.70-3.45 (10H, -O-CH2-, H2’, H3’, H4’, 
H5’, H6’, H4, H5, H6, m), 3.18  (3H, Hδ2, Hβ3, m), 2.94 (1H, Hβ3’, m), 2.80 (1H, Hβ1’, m), 
2.74 (1H, Hβ1, m), 2.66 (2H, -S-CH2-, m), 2.42 (2H, -CH2-CO-, t, J = 7.3 Hz), 2.25 (2H, 
H1, H3, m), 2.07 (2H, -N-CH2-CH2-, m), 1.90 (1H, Hβ2’, m), 1.82 (1H, Hβ2, m), 1.59 (5H, S-
CH2-CH2-, H2,eq, Hγ2, m), 1.49 (2H, -O-CH2-CH2-, m), 1.32-1.25 (5H, H2,ax, -O-CH2-CH2-
CH2-CH2-, m); HRMS (ESI, positive mode): m/z 642.3114 [M+2H]2+ (calcd mass for 
C46H84N28O12S2 [M+2H]
2+: 642.3132), m/z 428.5420 [M+3H]3+ (calcd mass for 
C46H85N28O12S2 [M+3H]
3+: 428.5448), m/z 321.6584 [M+4H]4+ (calcd mass for 
C46H86N28O12S2 [M+4H]
4+: 321.6605); analytical reversed-phase HPLC (0 a 25% B in 35 
min): Rt = 24.1 min. 
JanusB-NeaG4 (27). Yield: 23 %.  1H NMR (600 MHz, D2O) δ (ppm): 8.71 (1H, HAr, s), 
5.65 (1H, H1’, d, J = 4.0 Hz), 4.65 (1H, Hα3, m), 4.60 (1H, Hα1, t, J = 7.0 Hz), 4.34 (1H, 
Hα2, m), 4.21 (1H, -O-CH2-, m), 3.93 (2H, -N-CH2-, m), 3.82 (1H, -O-CH2-, m), 3.71 (3H, 
H2’, H5’, H6, m), 3.55 (4H, H4, H5, H3’, H4’, m), 3.48 (2H, H6’, m), 3.25 (1H, Hβ3, m), 3.17 
(2H, Hδ2, m), 2.96 (3H, -S-CH2-, Hβ3’, m), 2.81 (1H, Hβ1’, m), 2.72 (1H, Hβ1, m), 2.41 (2H, 
-CH2-CO, t, J = 7.2 Hz), 2.24 (2H, H1, H3, m), 2.07 (2H, -N-CH2-CH2-, m), 1.90 (1H, Hβ2’, 
m), 1.79 (2H, H2,eq, Hβ2, m), 1.62 (3H, H2,ax, Hγ2, m); HRMS (ESI, positive mode): m/z 
614.2806 [M+2H]2+ (calcd mass for C42H76N28O12S2 [M+2H]2+: 614.2819), m/z 409.8561 
[M+3H]3+ (calcd mass for C42H77N28O12S2 [M+3H]3+: 409.8572), m/z 307.6442 [M+4H]4+ 
(calcd mass for C42H78N28O12S2 [M+H]
+: 307.6449); analytical reversed-phase HPLC (0 a 
25% B in 35 min): Rt = 19.2 min. 
 
Evaluation of the interaction between Tau RNA and Janus-containing ligands. 
Oligoribonucleotides were synthesized using 2’-O-tert-butyldimethylsilyl (TBDMS) 
protection and following standard procedures (phosphite triester approach). RNA, 
fluorescein and 2-AP phosphoramidites, solid-supports, reagents and solvents for 
oligoribonucleotide synthesis were purchased from Glen Research or Link Technologies. 
The syntheses (1-µmol scale) were performed on an ABI 3400 DNA automatic synthesizer 
according to the manufacturer’s synthesis procedure, with some modifications.11a Cleavage 
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and deprotection from the solid support were carried out following a stepwise protocol.11a,28 
RNase-free reagents, solutions and materials were used when manipulating deprotected 
oligoribonucleotides. RNase-free water was obtained directly from a Milli-Q system 
equipped with a 5000 Da ultrafiltration cartridge. Reversed-phase high-performance liquid 
chromatography (HPLC) was used both for the analysis and purification of 
oligoribonucleotides using linear gradients of 0.1 M aqueous NH4HCO3, and a 1:1 mixture 
of 0.1 M aqueous NH4HCO3 and ACN. Characterization was carried out by high resolution 
MALDI-TOF mass spectrometry (negative mode, 2,4,6-trihidroxyacetophenone matrix 
with ammonium citrate as an additive).  
The following oligoribonucleotide sequences were synthesized (* label denotes that the 
ends of the chains were modified with 2’-O-methylribonucleosides): wt RNA: 
5’rG*C*GGCAGUGUGAGUACCUUCACACGUCC*C*; +3 mutated RNA: 
5’rG*C*GGCAGUGUAAGUACCUUCACACGUCC*C*; +16 mutated RNA: 
5’rG*C*GGCAGUGUGAGUACCUUCACAUGUCC*C*. In fluorescence binding assays, 
fluorescein was attached at the 5’-end of wt RNA, and the adenine in the loop of the +3 
mutated RNA sequence was replaced by 2-AP. NMR titration experiments were carried out 
with a shorter wt RNA sequence: 5’rGGCAGUGUGAGUACCUUCACACGUC. 
UV-monitored melting experiments. Melting curves were recorded by cooling the samples 
from 90 °C to 20 °C at a constant rate of 0.5 °C min−1 and measuring the absorbance at 
260 nm as a function of temperature. Then, the reverse denaturation curve (20 °C to 90 °C) 
was recorded. All experiments were repeated at least three times until coincident Tm values 
were obtained. The error in Tm values was ±0.2 °C. The solutions were 1 µM both in RNA 
(wt, +3 or +16) and in ligands, in 10 mM sodium phosphate buffer pH 6.8, 50 mM NaCl 
and 0.1 mM Na2EDTA. 
Fluorescence binding assays. Fluorescence measurements were performed in 1 cm path-
length quartz cells on a Quanta-Master fluorometer (PTI) at 25°C, with an excitation slit 
width of 10 nm and an emission slit width of 10 nm. Upon excitation at 290 nm, the 
emission spectrum was recorded over a range between 340 and 410 nm until no changes in 
the fluorescence intensity were detected. All binding assays were performed in the melting 
curves buffer with continuous magnetic stirring, except during the measurement. 
For each experiment, the fluorescence spectrum of 600 µL buffer solution without RNA or 
ligand was first taken, to be used as the baseline. Following this buffer blank, the spectrum 
of a 83 nM solution of refolded RNA containing 2-AP (600 µL) was recorded, and the 
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baseline blank subtracted. Subsequent aliquots of 1 µL of an aqueous ligand solution 
(increasing in concentration from 0 to 5.43 µM, depending on the ligand affinity) were 
added to the solution containing RNA, and the fluorescence spectrum was recorded after 
addition of each aliquot until the 2-AP fluorescence signal at 365 nm reached saturation 
(typically 5–10 min). Over the entire range of ligand concentrations, the emission maxima 
varied less than 1 nm. The total volume of the sample never changed more than 20%. The 
full titration was repeated in the absence of labelled RNA to correct for the presence of the 
ligand’s fluorescence. These spectra were subtracted from each corresponding point of the 
labelled RNA titrations, and the resulting fluorescence intensity was corrected for dilution 
(F*V/V0). The emission fluorescence at 365 nm was normalized by dividing the difference 
between the observed fluorescence, Fob, and the initial fluorescence, Fi, by the difference 
between the final fluorescence, Ff, and the initial fluorescence, Fi: FN = (Fob-Fi)/(Ff-Fi). This 
normalized fluorescence intensity (FN) was plotted as a function of the logarithm of the 
total ligand concentration. Finally, nonlinear regression using a sigmoidal dose–response 
curve was performed with the software package GraphPad Prism 4 (GraphPad Software, 
San Diego, CA) to calculate the EC50 values. Experimental errors were less than or equal to 
±25% of each value. 
NMR spectroscopy of RNA–ligand complexes. NMR spectra were acquired in a Bruker 
Advance spectrometer operating at 600 MHz and equipped with a cryoprobe. Samples of 
the complexes were prepared by mixing the appropriate amounts of RNA and ligand and 
performing an annealing protocol consisting of heating to 90 °C for 3 min, followed by 
snap cooling on ice for 20 min. Samples were dissolved in 10 mM sodium phosphate, pH 
6.8, in a 9:1 H2O-D2O mixture and NMR spectra were recorded at 5 °C to reduce the 
exchange with water. Water suppression was achieved by using an excitation sculpting 
sequence (zgesgp). 
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